27 Street Clair Avenue East
PO Box 305
Toronto, ON M4T 2M5
Canada
647-428-7031
https://www.archbiopartners.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees:
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Richard Gabriel Muruve | Co-Founder, CEO, Pres & Director | 74.37k | N/A | 1971 |
Dr. Daniel Abraham Muruve | Co-Founder, Chief Science Officer & Member of Scientific Advisory Board | N/A | N/A | N/A |
Mr. Andrew Bishop CFA | Acting CFO & Director | N/A | N/A | 1966 |
Dr. Justin MacDonald | Co-Founder & Principal Scientist | N/A | N/A | N/A |
Dr. Paul Beck | Co-Founder & Principal Scientist | N/A | N/A | N/A |
Arch Biopartners Inc., a biotechnology company, engages in the development of technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat dipeptidase-1 mediated organ inflammation in the lungs, liver, and kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is based in Toronto, Canada.
Arch Biopartners Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.